This update reviews treatment guidelines for managing axial spondyloarthritis, indicating evolving best practices.
We have reviewed and updated the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada (CRA/SPARCC) living treatment recommendations for the management of axial spondyloarthritis (axSpA).¹,² Since its initial publication, the panel felt the need to reassess recommendations relating to treatment with interleukin-17 inhibitors (IL-17i).
No takes yet. Share an insight, caveat, or question.
Richard et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: